FLUOXINE 500 Tablets

Form and presentation

Box of 10 tablets

Composition

Ciprofloxacine 500 mg / tablet

Indications

Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Adults

  • Lower respiratory tract infections due to Gram-negative bacteria.

            –    Exacerbations of chronic obstructive pulmonary disease

            –    Broncho-pulmonary infections in cystic fibrosis or in bronchiectasis

            –    Pneumonia

  • Chronic suppurative otitis media
  • Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria.
  • Urinary tract infections.
  • Gonococcal uretritis and cervicitis
  • Epididymo-orchitis including cases due to Neisseria gonorrhoeae.
  • Pelvic inflammatory disease including cases due to Neisseria gonorrhoeae. In the above genital tracts infections when thought or known to be due to Neisseria gonorrhoeae it is particularly important to obtain local information on the prevalence of resistance to ciprofloxacin and to confirm susceptibility based on laboratory testing.
  • Infections of the gastro-intestinal tract (e.g. travellers’ diarrhoea).
  • Intra-abdominal infections.
  • Infections of the skin and soft tissue caused by Gram-negative bacteria.
  • Malignant external otitis.
  • Infections of the bones and joints.
  • Treatment of infections in neutropenic patients.
  • Prophylaxis of infections in neutropenic patients.
  • Prophylaxis of invasive infections due to Neisseria meningitidis.
  • Inhalation anthrax (post-exposure prophylaxis and curative treatment).

Children and adolescents

  • Bronco-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa.
  • Complicated urinary tract infections and pyelonephritis.
  • Inhalation anthrax (post-exposure prophylaxis and curative treatment).

Ciprofloxacin may also be used to treat severe infections in children and adolescents when this is considered to be necessary.

Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.

Other products in this category